Stock Report

Download full stock data and analysis for free Last Updated: 31-Aug-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Auro Laboratories Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

BSE: 530233

₹232.20

up-down-arrow ₹0.20 (0.09%)

As on 28-Aug-2026IST

Market cap

info icon

₹145 Cr

Revenue (TTM)

info icon

₹37 Cr

P/E Ratio

info icon

30.9

P/B Ratio

info icon

3.1

Div. Yield

info icon

0 %

Edit peer-selector-edit
Auro Laboratories Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 145 35,497 29,798 16,589 15,507
Revenue (₹ Cr)
 37 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 4.68 1,018.97 497.77 603.02 270.18
Net Margin (%)
 12.08 10.47 20.72 22.63 23.29
RoE (%)
 10.63 21.30 28.49 19.61 14.45
Price to Earnings
 30.91 35.10 59.86 27.51 56.31
Price-To-Book
 3.05 6.79 14.74 4.76 7.48

Income Statement (₹ Cr)

Auro Laboratories Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
36.83 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
38.76 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
23.78 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
13.05 1,943.92 762.90 836.69 388.38
Depreciation arrow
3.45 425.10 98.11 78.88 74.78
EBIT arrow
9.60 1,518.82 664.79 757.81 313.60
Interest arrow
5.34 148.45 26.33 5.43 0.26
Other Income arrow
1.93 47.39 30.80 73.83 51.50
Exceptional Items arrow
-0.14 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
6.04 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
1.36 370.94 171.48 197.53 91.39
Profit after Tax arrow
4.68 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

Auro Laboratories Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
46.35 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
0.00 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
46.18 723.57 345.47 142.73 50.51
Current Liabilities arrow
28.56 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
121.08 9,514.48 2,930.14 4,157.10 2,231.79

Assets (₹ Cr)

Auro Laboratories Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
89.67 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
30.77 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
121.08 9,514.48 2,930.14 4,157.10 2,231.79
Total Debt* arrow
63.31 1,204.08 196.61 0.00 0.00
Net Current Assets arrow
2.21 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
2.86 258.92 13.18 4.82 3.76

Cashflow (₹ Cr)

Auro Laboratories Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
2.11 943.55 346.68 565.41 266.88
Cash Flow from Investing Activities arrow
-14.78 -1,193.06 -423.73 -570.15 -142.72
Cash from Financing Activities arrow
14.04 343.43 20.98 -64.34 -112.88
Net Cash Inflow / Outflow arrow
1.37 93.92 -56.08 -69.08 11.28

Ratios

Profitability Ratios

 Auro Laboratories Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
9.17 25.25 27.50 24.61 18.04
ROE (%) arrow
10.63 21.30 28.49 19.61 14.45
ROA (%) arrow
4.25 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
26.07 15.68 28.03 29.25 28.29
Net Margin (%) arrow
12.08 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Auro Laboratories Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
125.54 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
950.55 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
568.86 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
582.58 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
7.87 11.36 22.95 18.43 11.27

Valuation Ratios

 Auro Laboratories Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
30.29 34.38 59.86 26.64 55.82
Price / Book Value arrow
3.05 6.79 14.74 4.76 7.48
Dividend Yield (%) arrow
0.00 0.19 0.15 0.37 0.51
EV/EBITDA arrow
15.81 18.80 38.85 18.89 38.86
Market Cap (₹ Cr) arrow
165.16 30,257.56 15,412.11 11,956.86 10,627.92

Solvency Ratios

 Auro Laboratories Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.00 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
0.39 0.16 -- -- --
Current Ratio arrow
1.08 1.43 2.09 5.21 7.39
Quick Ratio arrow
0.60 0.82 1.37 3.85 5.46
Interest Coverage arrow
2.13 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 Auro Laboratories Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
24.85 26.46 22.82 41.42 41.52
Asset Turnover arrow
0.33 1.09 0.93 0.70 0.52
Receivable days arrow
110.10 88.68 77.32 144.58 169.86
Inventory Days arrow
102.16 84.11 80.83 96.67 97.92
Payable days arrow
327.89 176.65 125.94 135.45 159.68
Cash Conversion Cycle arrow
-115.63 -3.86 32.22 105.80 108.11
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...